These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 28306596)

  • 1. Biosimilars: implications for rheumatoid arthritis therapy.
    Cohen S; Kay J
    Curr Opin Rheumatol; 2017 May; 29(3):260-268. PubMed ID: 28306596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.
    Braun J; Kay J
    Expert Opin Drug Saf; 2017 Mar; 16(3):289-302. PubMed ID: 28068848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
    Yoo DH
    Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar monoclonal antibodies: the scientific basis for extrapolation.
    Schellekens H; Lietzan E; Faccin F; Venema J
    Expert Opin Biol Ther; 2015; 15(11):1633-46. PubMed ID: 26365396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience.
    Barker J; Girolomoni G; Egeberg A; Goncalves J; Pieper B; Kang T
    J Dermatolog Treat; 2020 Dec; 31(8):794-800. PubMed ID: 31094242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars: a systematic review of published and ongoing clinical trials of antipsoriatics in chronic inflammatory diseases.
    Nast A; Rosumeck S; Seidenschnur K
    J Dtsch Dermatol Ges; 2015 Apr; 13(4):294-300. PubMed ID: 25819235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world switching and discontinuation outcomes of infliximab biosimilars in patients with rheumatoid arthritis: A scoping review.
    Yin Y; McDermott C; Lockhart C
    J Manag Care Spec Pharm; 2023 Sep; 29(9):985-998. PubMed ID: 37610110
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis.
    Lu X; Hu R; Peng L; Liu M; Sun Z
    Front Immunol; 2021; 12():638444. PubMed ID: 33889152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T; Letkovsky J
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J; Kudrin A
    Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars in rheumatology: current perspectives and lessons learnt.
    Dörner T; Kay J
    Nat Rev Rheumatol; 2015 Dec; 11(12):713-24. PubMed ID: 26282080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars in inflammatory bowel disease.
    Gargallo CJ; Lué A; Gomollón F
    Minerva Med; 2017 Jun; 108(3):239-254. PubMed ID: 28176515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases.
    Rinaudo-Gaujous M; Paul S; Tedesco ED; Genin C; Roblin X; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2013 Oct; 38(8):914-24. PubMed ID: 24001128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars: From Extrapolation into Off Label Use.
    Zhao S; Nair JR; Moots RJ
    Curr Pharm Des; 2017; 23(44):6746-6751. PubMed ID: 29189127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The biosimilar road in inflammatory bowel disease: the right way?
    Fiorino G; Danese S
    Best Pract Res Clin Gastroenterol; 2014 Jun; 28(3):465-71. PubMed ID: 24913385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory diseases: Integrating biosimilars into clinical practice.
    Feldman SR
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S16-21. PubMed ID: 26058549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Experience with Biosimilars of Infliximab in Rheumatic Diseases.
    Azevedo VF; Kos IA; Ariello L
    Curr Pharm Des; 2017; 23(44):6752-6758. PubMed ID: 29189135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.